Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GLA-015 vs Oily Cannabidiol Solution
NCT04790136Phase 1Completed
- Sponsor
- SocraTec R&D
- Start
- Mar 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by SocraTec R&D. Primary endpoints: Area under the concentration-time curve from time 144 to 168 hours at steady state, Maximum plasma concentration from time 144 to 168 hours at steady state and 4 more. Started Mar 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04790136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790136.